HBV xAg Inhibitors
The compounds listed above are not direct inhibitors of HBV xAg but may indirectly influence its activity or the pathways it affects. The HBx protein is crucial for HBV replication and plays a role in modulating host cell pathways, contributing to liver disease progression. Antiviral drugs like Entecavir, Tenofovir, Lamivudine, Adefovir Dipivoxil, and Telbivudine primarily target HBV replication, which could indirectly affect the expression or activity of the HBx protein.
By targeting cancer cell proliferation and angiogenesis, kinase inhibitors like Sorafenib and Regorafenib may also influence pathways associated with HBx. Silymarin, Oxymatrine, and Silibinin are natural compounds with hepatoprotective and antiviral properties. They may exert indirect effects on HBx by modulating liver function and cellular responses to viral infection. Nilotinib and Cabozantinib, as tyrosine kinase inhibitors, might affect various signaling pathways in hepatocellular carcinoma and could indirectly influence the activity of HBx.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Entecavir | 142217-69-4 | sc-204738 sc-204738A sc-204738B | 1 mg 5 mg 25 mg | $75.00 $210.00 $620.00 | 11 | |
An antiviral drug potentially affecting HBx expression indirectly. | ||||||
Tenofovir | 147127-20-6 | sc-204335 sc-204335A | 10 mg 50 mg | $154.00 $633.00 | 11 | |
A nucleotide analog which may indirectly influence HBx activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A kinase inhibitor, used in hepatocellular carcinoma, potentially impacting HBx-related pathways. | ||||||
Lamivudine | 134678-17-4 | sc-221830 sc-221830A | 10 mg 50 mg | $102.00 $214.00 | 1 | |
An antiviral drug that may affect HBV replication and indirectly influence HBx expression. | ||||||
Adefovir dipivoxil | 142340-99-6 | sc-207260 sc-207260A | 50 mg 100 mg | $100.00 $246.00 | ||
An antiviral agent in research for hepatitis B, potentially impacting HBx activity indirectly. | ||||||
Silymarin group, mixture of isomers | 65666-07-1 | sc-301806 | 50 g | $319.00 | ||
A natural compound with hepatoprotective properties, potentially affecting HBx indirectly. | ||||||
Telbivudine | 3424-98-4 | sc-222340 sc-222340A | 10 mg 100 mg | $138.00 $1092.00 | 1 | |
An antiviral agent for chronic hepatitis B, which might indirectly influence HBx. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
A multikinase inhibitor, used in hepatocellular carcinoma, potentially impacting HBx-associated pathways. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
A tyrosine kinase inhibitor, potentially affecting signaling pathways associated with HBx. | ||||||
Silybin | 22888-70-6 | sc-202812 sc-202812A sc-202812B sc-202812C | 1 g 5 g 10 g 50 g | $54.00 $112.00 $202.00 $700.00 | 6 | |
A component of silymarin with hepatoprotective and potential antiviral effects, possibly influencing HBx. | ||||||